Here we’ll bring you 10 innovative biotech companies that have drawn significant Series A and Series B investments in Q1 2023, showcasing BOLD solutions for patients globally.
-
CARGO Therapeutics
: developing next-generation CAR-T cell therapies that incorporate complex therapeutics cargo with the potential to achieve durable responses that are curative for more cancer patients. ($200M Series A)
-
Paratus Sciences
: understanding the unique attributes of bat biology such as the ability to control inflammation, tolerate viral infection, resist cancer, and apply these insights to identify and develop therapeutics for a myriad of diseases. ($100M Series A)
-
Rapport Therapeutics
: creating therapeutics that precisely target the subset of neurons where neurological disorders originate. ($100M Series A)
-
Mediar Therapeutics
: advancing a new approach to fibrosis treatment that halts the disease by targeting the fibrotic mediators that drive disease progression. ($85M Series A)
-
Volastra Therapeutics
: developing novel approaches to treat cancer by exploiting a unique tumor vulnerability known as chromosomal instability (CIN). ($80M Series A)
-
Aera Therapeutics
: advancing proprietary delivery platform based on endogenous human proteins. Offers the potential to enable genetic medicines across a broad range of modalities and therapeutic areas. ($193M Series A and B)
-
ArriVent Biopharma
: aiming to globalize medicines for patients with unmet medical needs in a broad range of diseases, with an initial focus on oncology. ($155M Series B)
-
Chroma Medicine
: advancing a new class of genomic medicines that harness epigenetics, nature's innate mechanism for gene regulation, to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. ($135M Series B)
-
Hemab Therapeutics
: developing monoclonal and bispecific antibody-based therapeutics for serious, underserved bleeding and thrombotic disorders. ($135M Series B)
-
Flare Therapeutics
: identifying novel druggable pockets within transcription factor complexes to discover small molecule precision medicines for cancer and other diseases. ($123M Series B)
